Why the study?
Does the novel renin inhibitor KRI-1314 reduce blood pressure and plasma renin activity in preclinical models?
Population
In vitro human and Japanese monkey plasma, and in vivo sodium-depleted Japanese monkeys
Design
Preclinical
Follow-up
up to 5 hours post-administration
Authors
Loading...
Does not support clinical use; extends preclinical evidence for oral renin inhibition but leaves translation open.
Does the novel renin inhibitor KRI-1314 reduce blood pressure and plasma renin activity in preclinical models?
KRI-1314 is a potent, orally effective renin inhibitor that lowers blood pressure in preclinical models, suggesting potential as a novel antihypertensive agent.
Miyazaki et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: